Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1752935

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1752935

Depression Drugs

PUBLISHED:
PAGES: 380 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Depression Drugs Market to Reach US$20.1 Billion by 2030

The global market for Depression Drugs estimated at US$17.9 Billion in the year 2024, is expected to reach US$20.1 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Atypical Antipsychotics, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Serotonin-Norepinephrine Reuptake Inhibitors segment is estimated at 1.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 3.6% CAGR

The Depression Drugs market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Depression Drugs Market - Key Trends & Drivers Summarized

Why Does the Demand for Depression Drugs Continue to Escalate Worldwide?

Depression remains one of the most prevalent and debilitating mental health disorders globally, driving sustained demand for pharmacological treatments. Major depressive disorder (MDD), bipolar depression, dysthymia, and seasonal affective disorder collectively account for a substantial share of the global mental illness burden. The ongoing rise in diagnosed cases-partly fueled by growing public awareness, reduced stigma, and improved access to psychiatric care-has led to a consistent increase in the prescription of antidepressant medications. Additionally, recent global events, including economic stress, conflict, and pandemic-related isolation, have heightened the need for effective, scalable mental health solutions.

Depression drugs serve a critical role in stabilizing neurochemical imbalances and alleviating symptoms such as persistent sadness, lack of motivation, and suicidal ideation. Antidepressants are also frequently prescribed for off-label uses such as chronic pain, anxiety, and sleep disorders, expanding their therapeutic utility. As healthcare systems prioritize mental health and integrate it into primary care models, antidepressant therapy is becoming a frontline treatment option, driving growth in both generic and branded drug segments.

How Are Drug Classes and Novel Mechanisms of Action Evolving to Meet Clinical Needs?

The depression drug market comprises several well-established classes, including Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), and Monoamine Oxidase Inhibitors (MAOIs). SSRIs and SNRIs dominate prescriptions due to their favorable safety profiles, ease of use, and broad applicability. However, limitations such as delayed onset of action, partial response, and side effects including weight gain and sexual dysfunction have underscored the need for alternative treatments.

This has led to the emergence of newer agents with novel mechanisms of action. Atypical antidepressants targeting glutamatergic pathways, such as NMDA receptor antagonists, are gaining attention for their rapid-acting effects. Esketamine nasal spray, for example, offers fast symptom relief in treatment-resistant depression. Meanwhile, drugs modulating melatonin receptors and other neuropeptides are under investigation to address circadian rhythm disruptions associated with depressive states. These innovations mark a significant shift from monoamine-targeting therapies to neurocircuitry modulation, promising more personalized and fast-acting treatment options.

What Are the Regulatory and Commercial Trends Influencing Market Competition?

Patent expiries of major antidepressants have created a robust generic drug landscape, particularly in mature markets, intensifying price competition and improving affordability. However, this has also pushed pharmaceutical companies to invest in differentiated therapies targeting unmet needs, such as treatment-resistant depression, adolescent and pediatric depression, and depression with co-morbid anxiety or substance abuse. Fast-track regulatory approvals, orphan designations, and breakthrough therapy statuses are being granted to innovative drugs that demonstrate clinical value in hard-to-treat populations.

Pharma companies are also leveraging lifecycle management strategies, including extended-release formulations, combination therapies, and novel delivery systems to sustain brand exclusivity. Partnerships between biotech firms and mental health startups are facilitating drug development using digital biomarkers and AI-based patient monitoring. These tools are helping identify more responsive subgroups, monitor adherence, and measure real-time outcomes, making depression drug development increasingly data-driven and patient-centric.

What Are the Primary Forces Propelling Growth in the Depression Drugs Market?

The growth in the depression drugs market is driven by several factors, including rising mental health burden across age groups, expanding diagnosis rates, and the continued shift toward pharmacological intervention as a first-line treatment. The integration of mental health services into primary and telehealth care platforms is making antidepressants more accessible, while broader insurance coverage for mental health conditions is removing cost-related treatment barriers. This is especially critical in emerging economies where infrastructure is improving and cultural stigma around psychiatric care is gradually diminishing.

Scientific advancements in neurobiology are enabling the discovery of faster-acting and more targeted therapies, appealing to both physicians and patients seeking quicker symptom resolution. Additionally, the growing focus on individualized treatment pathways is fostering demand for diversified drug classes and delivery systems. As public health systems prioritize early intervention and continuity of care for depression, pharmaceutical innovation, digital therapeutics integration, and expanded treatment guidelines will continue to drive market expansion in both developed and emerging regions.

SCOPE OF STUDY:

The report analyzes the Depression Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Other Drug Classes); Drug Type (Generic Drugs, Branded Drugs); Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Other Disorders)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Alkermes plc
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Lupin Limited
  • Luye Pharma Group Ltd.
  • Novartis International AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36686

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Depression Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Major Depressive Disorder Propels Long-Term Demand for Antidepressant Therapies
    • Increased Mental Health Awareness and Screening Strengthens Early Diagnosis and Treatment Rates
    • Expansion of Telepsychiatry and Digital Prescribing Channels Throws the Spotlight on Medication Access
    • Growth in SSRI and SNRI Drug Classes Continues to Dominate First-Line Depression Management
    • Innovation in Fast-Acting Antidepressants Fuels Market Differentiation
    • Regulatory Approvals for Novel Mechanisms Expand the Treatment Toolbox
    • Rising Demand for Personalized Psychiatry Supports Pharmacogenomic-Guided Drug Selection
    • Shift Toward Combination Therapy and Adjunctive Treatments Enhances Use of Atypical Antidepressants
    • Increased Focus on Adherence, Side Effects, and Tolerability Drives Extended-Release Formulation R&D
    • Integration of Digital Therapeutics With Drug Therapy Enhances Monitoring and Outcome Tracking
    • Mental Health Coverage Expansion in Insurance Policies Supports Prescription Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Depression Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Depression Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Atypical Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Selective Serotonin Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Central Nervous System Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Tricyclic Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Monoamine Oxidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Major Depressive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Obsessive-Compulsive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Generalized Anxiety Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Panic Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • JAPAN
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • CHINA
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • EUROPE
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Depression Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • FRANCE
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • GERMANY
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Depression Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • INDIA
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Depression Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Depression Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
  • AFRICA
    • Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!